Advertisement
UK markets close in 8 hours 2 minutes
  • FTSE 100

    8,437.14
    +16.88 (+0.20%)
     
  • FTSE 250

    20,805.37
    +55.47 (+0.27%)
     
  • AIM

    807.64
    +13.62 (+1.72%)
     
  • GBP/EUR

    1.1674
    -0.0004 (-0.04%)
     
  • GBP/USD

    1.2690
    -0.0016 (-0.12%)
     
  • Bitcoin GBP

    52,533.30
    -434.70 (-0.82%)
     
  • CMC Crypto 200

    1,360.23
    +5.81 (+0.43%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.19 (+0.34%)
     
  • CRUDE OIL

    80.22
    +0.16 (+0.20%)
     
  • GOLD FUTURES

    2,445.40
    +28.00 (+1.16%)
     
  • NIKKEI 225

    39,069.68
    +282.30 (+0.73%)
     
  • HANG SENG

    19,619.32
    +65.71 (+0.34%)
     
  • DAX

    18,734.43
    +30.01 (+0.16%)
     
  • CAC 40

    8,176.55
    +9.05 (+0.11%)
     

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

LAVA Therapeutics N.V.
LAVA Therapeutics N.V.

UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2)

T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.

Presentation Details
Format: Fireside Chat
Date: Monday, May 13, 2024
Time: 10:00 a.m. ET

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events. The replay will be archived for 90 days following the presentation date.

ADVERTISEMENT

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.

A Phase 1/2a dose escalation trial (NCT05369000) to evaluate the lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States in a trial evaluating monotherapy and with interleukin-2 (IL-2). The Company is also expanding the Phase 1/2a study to include a combination arm with KEYTRUDA®(pembrolizumab), through a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. The Company licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for clinical development and commercialization. The pipeline also includes several pre-clinical programs. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedInX, and YouTube.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA

Gammabody® is a registered trademark of LAVA Therapeutics N.V.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

LifeSci Advisors (IR/Media)
Joyce Allaire
Jallaire@lifesciadvisors.com